D. E. Shaw & Co., Inc. Biomarin Pharmaceutical Inc Put Options Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $1.23 Million - $1.56 Million	-17,100 Reduced 47.37%	19,000 $1.68 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $1.28 Million - $1.46 Million	17,100 Added 90.0%	36,100 $2.79 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $2.27 Million - $2.54 Million	-30,000 Reduced 61.22%	19,000 $1.59 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $672,570 - $816,210	9,000 Added 22.5%	49,000 $3.7 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $2.11 Million - $3.85 Million	29,400 Added 277.36%	40,000 $3.04 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $2.34 Million - $3.65 Million	-29,400 Reduced 73.5%	10,600 $1.31 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $2.14 Million - $2.91 Million	30,000 Added 300.0%	40,000 $3.38 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $803,500 - $939,000	-10,000 Reduced 50.0%	10,000 $857,000
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $1.61 Million - $1.9 Million	20,000	20,000 $1.86 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.